{"id":"NCT02027428","sponsor":"Celgene","briefTitle":"Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer","officialTitle":"A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (AbraxaneÂ®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-11","primaryCompletion":"2017-09-15","completion":"2019-08-01","firstPosted":"2014-01-06","resultsPosted":"2018-12-07","lastUpdate":"2020-08-17"},"enrollment":427,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Cell Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Abraxane (Induction)","otherNames":["nab-paclitaxel"]},{"type":"DRUG","name":"Carboplatin (Induction)","otherNames":[]},{"type":"DRUG","name":"Abraxane (Maintenance)","otherNames":[]},{"type":"OTHER","name":"Best Supportive Care (Maintenance)","otherNames":[]},{"type":"DRUG","name":"Abraxane (Induction)","otherNames":["nab-paclitaxel"]},{"type":"DRUG","name":"Carboplatin (Induction)","otherNames":[]},{"type":"OTHER","name":"Best Supportive Care (Maintenance)","otherNames":[]}],"arms":[{"label":"Abraxane + Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"label":"Best Supportive Care (BSC)","type":"OTHER"}],"summary":"Maintenance treatment of advanced stage squamous cell NSCLC.\n\nPhase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin as induction in subjects with stage IIIB/IV squamous cell NSCLC.\n\nSubjects who discontinued treatment from the maintenance part for any reason other than withdrawal of consent, lost to follow-up, or death, were entered into a Follow-up period that had a visit 28 days after progression or discontinuation.\n\nThose who entered Follow-up without progression continued with follow-up scans according to standard of care (SOC) until documentation of progression of disease. Additionally, subjects were followed for OS by phone approximately every 90 days for a minimum of 18 months, for up to approximately 5 years after the last subject was randomized.","primaryOutcome":{"measure":"Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance","timeFrame":"From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months","effectByArm":[{"arm":"Nab-Paclitaxel + Best Supportive Care (BSC)","deltaMin":3.12,"sd":null},{"arm":"Best Supportive Care (BSC)","deltaMin":2.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3486"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":119,"countries":["United States","Germany","Italy","Spain","United Kingdom"]},"refs":{"pmids":["29138610","29089791","30149366","29878040","30773308","30209750","30115475","30180593","30014884","29770997","30087851","30087850","29946913","29936064","29932294","29658592","30243879","30442938","30383906","30100104","30529902","30519122","30503309","30497432","30166402","29846848","30623229","30006989","30739019","30863113","30481287","30881017","30933354","31002261","30768369"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":177,"n":420},"commonTop":["Anaemia","Neutropenia","Peripheral sensory neuropathy","Nausea","Fatigue"]}}